|
Anxiety symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Administration of PPARA agonists decreases amyloid pathology and reverses memory deficits and anxiety symptoms in APP-PSEN1ΔE9 mice.
|
30898012 |
2020 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
In Ad cases, both APP and p-APP were significantly associated with clinical stages (APP and p-APP), pathologic T (p-APP), and pathologic N (APP and p-APP) of the cases examined.
|
31138460 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Similarly, aATP+APP programming showed no significant difference in AF progression (odds ratio 0.65; 95% CI 0.36-1.14; P = .13; I<sup>2</sup> = 61%).
|
30772532 |
2019 |
|
Iron Metabolism Disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Dietary iron overload induces iron disorder and Aβ and phospho-τ expression in the hippocampus of adult WT and APP/PS1 transgenic mice.
|
31373375 |
2019 |
|
Hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reduced O-GlcNAcylation of APP and Tau due to hypoglycemia is found to be associated with their pathological features in AD brain.
|
31143098 |
2019 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, their hepatoprotective effect on human hepatoma HepG2 cells in vitro and in an animal model of fatty liver disease was evidenced by the findings that APPI and APPII diminished lipid deposit in cells, blood and the liver, increased cellular antioxidant activity and viability, and protected the liver against injury.
|
31548551 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the effect and mechanism of roflumilast, an FDA-approved PDE4 inhibitor for treatment of chronic obstructive pulmonary disease (COPD), on learning and memory abilities in the APP/PS1 mouse model of Alzheimer's disease (AD).
|
30610438 |
2019 |
|
Marijuana Abuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
The non-psycho active component of Cannabis sativa, CBD has previously been shown to protect against the neurotoxic effects of beta amyloid peptide (Aβ) in cell culture and cognitive behavioural models of neurodegeneration.
|
29574668 |
2019 |
|
Atrial Premature Complexes
|
0.010 |
Biomarker
|
disease |
BEFREE |
APP algorithm reduced premature atrial complexes (PAC) burden (mean difference [MD] -1117.74; 95% CI -1852.36 to -383.11; P = .003; I<sup>2</sup> = 67%) but did not decrease AF burden (MD 8.20; 95% CI -5.39 to 21.80; P = .24; I<sup>2</sup> = 17%) or AF episodes (MD 0.00; 95% CI -0.24 to 0.25; P = .98; I<sup>2</sup> = 0%).
|
30772532 |
2019 |
|
Sinus Thrombosis, Intracranial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We describe a 47-year-old patient with Iowa-type amyloid precursor protein (APP) mutation-related hereditary CAA that manifested with concomitant lobar hemorrhage and venous sinus thrombosis.
|
31640101 |
2019 |
|
Sleep Apnea Syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we exposed an AD-relevant mouse model (APP/PS1 KI) to chronic intermittent hypoxia (IH) (an experimental model of sleep apnea) to begin to describe one of the potential mechanisms by which SDB could increase the risk of dementia.
|
30529693 |
2019 |
|
Subarachnoid Hemorrhage
|
0.010 |
Biomarker
|
disease |
BEFREE |
SAH induced WMI shown as the accumulation of amyloid precursor protein and neurofilament heavy polypeptide as well as myelin loss.
|
30703614 |
2019 |
|
Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this work, we have developed small-sized (with diameter of ∼4.7 nm) and positively charged fluorescent conjugated polymer nanoparticles (CPNPs) with strong inhibition effect on Aβ<sub>1-40</sub> peptides fibrillation.
|
31148450 |
2019 |
|
Decrease in appetite
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Four appetite and protein intake strata were identified based on simplified nutritional appetite questionnaire (SNAQ) scores (≤14 versus >14) and the probability of a protein intake below 1.0 g/kg adjusted BW/day (≥0.3 versus <0.3) based on the 14-item Pro55+ screener: "appi"-Poor appetite and lower level of protein intake (12.2%); "APpi"-Good appetite but lower level of protein intake (25.5%); "apPI"-Poor appetite but higher level of protein intake (14.8%); and "APPI"-Good appetite and higher level of protein intake (47.5%).
|
30987278 |
2019 |
|
Pervasive Development Disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Novel Contribution of Secreted Amyloid-β Precursor Protein to White Matter Brain Enlargement in Autism Spectrum Disorder.
|
31024350 |
2019 |
|
Metabolic Syndrome X
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, it discussed potential mechanisms involved in the APPs-induced MetS and NAFLD.
|
31413575 |
2019 |
|
Disorder of olfactory system
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we studied the morphological and functional changes induced by dendrodendritic inhibition in GCs onto MCs in the OB of amyloid precursor protein (APP)/PS1 mice and age-matched control mice during aging, particular, we focused on the effects of olfactory disorder in the dendrodendritic synaptic structures and the LFPs.
|
30740049 |
2019 |
|
Cerebritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits.
|
30610193 |
2019 |
|
Chlamydia pneumoniae Infections
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that Chlamydia pneumoniae infection of human astrocytes alters the expression of the amyloid precursor protein (APP)-processing secretases, ADAM10, BACE1, and PSEN1, to promote β-amyloid formation.
|
30786875 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression of APP and COL1A2 was validated in HNSCC samples.
|
31304688 |
2019 |
|
Glial scar
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our results suggest that WaD may be involved in non-ischemic CC and striatum after focal cortical infarction, accompanied by APP aggregation and neuroglia initiation forming the glial scar.
|
31051228 |
2019 |
|
Autism Spectrum Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
Novel Contribution of Secreted Amyloid-β Precursor Protein to White Matter Brain Enlargement in Autism Spectrum Disorder.
|
31024350 |
2019 |
|
Multiple Chronic Conditions
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
γ-Secretase is a multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and processive manner.
|
29619615 |
2019 |
|
Decreased Concentration
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, we found a suppression of Aβ plaques and decreased concentration of Aβ<sub>1-42</sub> in the hippocampus of APP/PS1 mice following treatment.
|
30870684 |
2019 |
|
Mitochondrial abnormalities
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Excessive generation and accumulation of amyloid-β (Aβ) fragments by familial mutations of amyloid precursor protein (APP) and presenilin 1 (PS1) play a key role in causing oxidative stress, mitochondrial abnormalities and neuronal apoptosis in Alzheimer's disease (AD).
|
31159590 |
2019 |